# Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults

> **NCT02071082** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 79 (actual)

## Conditions studied

- HIV
- HBV

## Interventions

- **DRUG:** E/C/F/TAF

## Key facts

- **NCT ID:** NCT02071082
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-25
- **Primary completion:** 2015-01-23
- **Final completion:** 2016-10-26
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02071082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02071082, "Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02071082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*